← Back

Wuhan Hvsen Biotechnology Co Ltd

Wuhan Hvsen Biotechnology Co., Ltd. researches, develops, and manufactures macrolide APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials, florfenicol, cefquinome sulfate, and tildipirosin injections, as well as florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company also produces veterinary drug raw materials and preparations, along with traditional Chinese medicine extractives. Founded in 2002, it is based in Wuhan, China.

Country
Price · split & dividend adjusted
News & notes moving 300871.CS
300871.CS2

Huisheng Bio's 2026 interim net profit reaches 206 million yuan, up 75.59% year-on-year

Huisheng Bio released its 2026 interim report, with net profit attributable to the parent company of 206 million yuan, up 75.59% from the same period last year. Total operating revenue was 865 million yuan, up 5.20% year-on-year, and net operating cash inflow was 128 million yuan, up 3.57% year-on-year. The company's latest gross margin was 35.72%, rising for six consecutive quarters, and its latest return on equity was 8.89%, up 3.20 percentage points from the same period last year. Diluted earnings per share were 1.02 yuan, up 53.56% year-on-year.
Jiemian·32dRead more →
300871.CS

Huisheng Bio Provides Joint Liability Guarantee for 60 Million Yuan Loan to Wholly-Owned Subsidiary Xinjiang Huisheng

Wuhan Huisheng Biotechnology has provided a joint liability guarantee for a 60 million yuan fixed asset loan to its wholly-owned subsidiary Xinjiang Huisheng Biotechnology. The company signed a guarantee contract with the Bank of China Yili Kazakh Autonomous Prefecture Branch. This guarantee falls within the 2026 annual guarantee quota and does not require further approval from the board of directors or shareholders' meeting. Xinjiang Huisheng was established in November 2025 with a registered capital of 300 million yuan and is currently in the construction phase, not yet fully operational. After this guarantee, the actual guarantee balance of the company and its controlled subsidiaries is 218.18 million yuan, accounting for 10.04% of the audited net assets in 2025. All guarantees are within the scope of consolidated financial statements, with no overdue guarantees or guarantees involved in litigation. The company has previously obtained approval to provide guarantees not exceeding 600 million yuan for its consolidated subsidiaries in 2026.
Jiemian·38dRead more →